At the news
? NEUTRALIMPACT 9/10 8-K filed Apr 27, 2026 at 11:43 ET
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting from Nasdaq, and termination of its credit agreement. All directors and executive officers resigned, with BioMarin appointing new leadership. Shareholders received $14.50 per share in cash.
- Merger with BioMarin Pharmaceutical completed on April 27, 2026, with Amicus becoming a wholly owned subsidiary.
- Shareholders received $14.50 per share in cash as merger consideration.
- Company common stock to be delisted from Nasdaq; Form 25 filed for deregistration.
- All nine directors and five executive officers resigned; BioMarin appointees took over leadership roles.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access